Enterovirus-Specific Anti-peptide Antibodies

Area of Science:

• Virology
• Immunology
• Vaccine Development

Background:

• Enterovirus 71 (EV-71) causes hand, foot, and mouth disease (HFMD), with recent outbreaks showing severe neurological complications and high mortality.
• Existing inactivated EV-71 vaccines face manufacturing and cost challenges, limiting accessibility in developing nations.

Purpose of the Study:

• To explore the potential of synthetic peptides as a cost-effective strategy for developing broadly protective EV-71 vaccines.
• To generate and characterize cross-neutralizing antibodies against EV-71 using peptide-based immunogens.

Main Methods:

• In silico analysis to select immunogenic EV-71 peptides.
• Conjugation of selected EV-71 B-cell epitopes to a promiscuous T-cell epitope from Poliovirus.
• Immunization of animals with peptide-carrier conjugates and evaluation of anti-peptide antibody neutralizing activity.

Main Results:

• Production of cross-neutralizing antibodies elicited by immunization with synthetic EV-71 peptides.
• Demonstrated in vitro neutralization of EV-71 by these antibodies.
• Observed cross-reactivity of neutralizing antibodies against other enteroviruses, including CVA16, CVB4, CVB6, and ECHO13.

Conclusions:

• Synthetic peptides conjugated to carrier proteins can elicit potent neutralizing antibodies against EV-71.
• This peptide-based approach offers a promising, cost-effective alternative for developing vaccines against EV-71 and related enteroviruses.
• The cross-neutralizing potential highlights a strategy for broader enterovirus vaccine development.